ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 0233

Abatacetp in Spanish Patients with Arthritis Rheumatoid and Interstitial Lung Disease. Multicenter Study of 263 Patients

C. Fernandez-Diaz1, Santos Castañeda2, Rafael Melero3, Francisco Miguel Ortiz Sanjuan4, Antonio Juan-Mas5, Carmen Carrasco Cubero6, Raquel Almodovar7, Sebastian Rodriguez-Garcia8, C. Aguilera-Cros9, Ignacio Villa10, S. Ordoñez11, Enrique Raya12, C. Ojeda13, Manuel Jose Moreno-Ramos14, Gema Bonilla15, Susana Romero-Yuste16, Ana Ruibal-Escribano17, Jose Luis Andreu Sanchez18, R. Exposito19, Javier Loricera20, Natalia Mena-Vazquez21, Ana Urriticoechea22, C. Peralta23, Luis Arboleya24, Francisco Javier Narváez25, O. Maiz26, Julia Fernandez Melon27, P Vela28, Ivan Castellvi29, I. Cabezas30, Alejandra Lopez Robles31, Patricia Carreira Delgado32, Juan M. Blanco-Madrigal33, N. Del-val-del-amo34, E Salgado35, B. Garcia-magallon36, Cristina Hidalgo Calleja37, Mireia Corbeto Lopez38, A. Perez39, S. Castro40, Juan Ramón De dios41, Andrea García Valle42, R Lopez43, Angel García Aparicio44, EC Cervantes45, C Gonzalez46, N Alvarez-Rivas47, L. Perez48, Miguel Ángel González-Gay49 and Ricardo Blanco50, 1H. Marqués de Valdecilla, Madrid, Spain, 2Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, 3CHU. VIgo, Vigo, Spain, 4Rheumatology Department, HUP La Fe, Valencia, Spain, 5Son Llàzer University Hospital, Mallorca, Spain, 6H. Mérida, Mérida, Spain, 7Fundación Alcorcón University Hospital, Madrid, 8La Princesa University Hospital, Madrid, Spain, 9H.Virgen del Rocio, Sevilla, Spain, 10H. Torrelavega, Santander, Spain, 11H. Arnau Vilanova, LLeida, Spain, 12San Cecilio Clinic Universitary Hospital, Granada, Spain, 13H. Virgen de la Macarena, Sevilla, Spain, 14Arrixaca University Hospital, Murcia, 15Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, 16H Pontevedra, Coruna, Spain, 17Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, 18Hospital Universitario Puerta de Hierro, Majadahonda, Spain, 19H. Laredo, Laredo, Spain, 20Hospital Universitario Marqués de Valdecilla, Santander, Spain, 21Hospital Regional Universitario de Málaga, Málaga, Spain, 22Can Misses, Ibiza, Spain, 23H. Clinico Zaragoza, Zaragoza, Spain, 24H. Oviedo, Oviedo, Spain, 25Hospital Bellvitge, BARCELONA, Spain, 26H. Donosti, Donosti, Spain, 27H. Son Espases, Mallorca, Spain, 28H Alicante, Alicante, Spain, 29Hospital Santa Creu i Sant Pau, Barcelona, Spain, 30H. Río Ortega, Valladolid, Spain, 31H. León, León, 32H. 12 de octubre, Madrid, Spain, 33Basurto University Hospital, Bilbao, Spain, 34Complejo Hospitalario de Navarra, Pamplona, Spain, 35CHU Ourense, Ourense, Spain, 36H. Huesca, Zaragoza, Spain, 37Hospital Universitario Salamanca, Salamanca, Spain, 38Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, 39H. Puerta del Mar, Cadiz, Spain, 40H. Joan XXIII, Tarragona, Spain, 41H. Alava, Alava, Spain, 42H. Palencia, Palencia, Spain, 43H. Negrin, Las Palmas, Spain, 44H. Mostoles, Madrid, Spain, 45H. Santiago de compostela, Santiago, Spain, 46H. Valladolid, Valladolid, Spain, 47H. S Agustin, Aviles, Spain, 48Hospital Universitario Virgen de las Nieves, Granada, Spain, 49Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 50Hospital Universitario Marques de Valdecilla, Santander, Spain

Meeting: ACR Convergence 2020

Keywords: , ,

Session Information

Date: Friday, November 6, 2020

Session Title: RA – Treatments Poster I: RA Treatments & Their Safety

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: To assess the efficacy of abatacept (ABA) in Rheumatoid Arthritis (RA) patients with Interstitial Lung Disease (ILD) (RA-ILD).

Methods: Observational multicenter study of RA-ILD patients treated with at least 1 dose of ABA. ILD was diagnosed by high-resolution computed tomography (HRCT). We analyzed the following variables at baseline (ABA initiation), 12 months, and at the end of the follow-up: a) Modified Medical Research Council (MMRC) scale (1-point change), b) Forced Vital Capacity (FVC) or Diffusion Lung Capacity for Carbon Monoxide (DLCO) (improvement or worsening ≥10%), c) HRCT, d) DAS28ESR, and e) corticosteroid sparing effect

Results: We studied 263 RA-ILD patients (150 women/113 men; mean age 64.6±10 years). At baseline, they had a median duration of ILD of 1 [0.25-3.44] years, moderate or severe degree of dyspnea (MMRC grade 2, 3 or 4) (40.3%), FVC (% of the predicted) mean±SD 85.9±21.8%, DLCO (% of the predicted) 65.7±18.3, and DAS28ESR: 4.5±1.5. The ILD patterns were: Usual Interstitial Pneumonia (UIP) (40.3%), Non-Specific Interstitial Pneumonia (NSIP) (31.9%), and others (27.8%). ABA was prescribed at standard dose, intravenously (25.5%) or subcutaneously (74.5%). After a median follow-up of 12 [6-36] months the following variables did not show worsening: dyspnea (MMRC) (91.9%); FVC (87.7%); DLCO (90.6%); chest HRCT (76.6%). A significant improvement of DAS28ESR from 4.5±1.5 to 3.1±1.3 at the end of follow-up (p< 0.001) and a corticosteroid sparing effect from a median 7.5 [5-10] mg/day to 5 [2.5-7.5] mg/day at the end of follow-up; p < 0.001 was also observed. ABA was withdrawn in 62 (23.6%) patients due to adverse events (n=30), articular inefficacy (n=27), ILD worsening (n=3), and other causes (n=2).

Conclusion: ABA may be an effective and safe treatment for patients with RA-ILD.

Disclosure: C. Fernandez-Diaz, None; S. Castañeda, Roche, 2; R. Melero, None; F. Ortiz Sanjuan, None; A. Juan-Mas, None; C. Carrasco Cubero, None; R. Almodovar, None; S. Rodriguez-Garcia, None; C. Aguilera-Cros, None; I. Villa, None; S. Ordoñez, None; E. Raya, None; C. Ojeda, None; M. Moreno-Ramos, None; G. Bonilla, None; S. Romero-Yuste, None; A. Ruibal-Escribano, None; J. Andreu Sanchez, None; R. Exposito, None; J. Loricera, None; N. Mena-Vazquez, None; A. Urriticoechea, None; C. Peralta, None; L. Arboleya, None; F. Narváez, None; O. Maiz, None; J. Fernandez Melon, None; P. Vela, None; I. Castellvi, None; I. Cabezas, None; A. Lopez Robles, None; P. Carreira Delgado, None; J. Blanco-Madrigal, None; N. Del-val-del-amo, None; E. Salgado, None; B. Garcia-magallon, None; C. Hidalgo Calleja, None; M. Corbeto Lopez, None; A. Perez, None; S. Castro, None; J. De dios, None; A. García Valle, None; R. Lopez, None; A. García Aparicio, None; E. Cervantes, None; C. Gonzalez, None; N. Alvarez-Rivas, None; L. Perez, None; M. González-Gay, None; R. Blanco, None.

To cite this abstract in AMA style:

Fernandez-Diaz C, Castañeda S, Melero R, Ortiz Sanjuan F, Juan-Mas A, Carrasco Cubero C, Almodovar R, Rodriguez-Garcia S, Aguilera-Cros C, Villa I, Ordoñez S, Raya E, Ojeda C, Moreno-Ramos M, Bonilla G, Romero-Yuste S, Ruibal-Escribano A, Andreu Sanchez J, Exposito R, Loricera J, Mena-Vazquez N, Urriticoechea A, Peralta C, Arboleya L, Narváez F, Maiz O, Fernandez Melon J, Vela P, Castellvi I, Cabezas I, Lopez Robles A, Carreira Delgado P, Blanco-Madrigal J, Del-val-del-amo N, Salgado E, Garcia-magallon B, Hidalgo Calleja C, Corbeto Lopez M, Perez A, Castro S, De dios J, García Valle A, Lopez R, García Aparicio A, Cervantes E, Gonzalez C, Alvarez-Rivas N, Perez L, González-Gay M, Blanco R. Abatacetp in Spanish Patients with Arthritis Rheumatoid and Interstitial Lung Disease. Multicenter Study of 263 Patients [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/abatacetp-in-spanish-patients-with-arthritis-rheumatoid-and-interstitial-lung-disease-multicenter-study-of-263-patients/. Accessed April 14, 2021.

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/abatacetp-in-spanish-patients-with-arthritis-rheumatoid-and-interstitial-lung-disease-multicenter-study-of-263-patients/